What do systematic reviews say?

Mycophenolate mofetil vs cyclosporin

Mycophenolate mofetil may leads to lower adverse effects: gum hypertrophy compared with cyclosporin (low certainty).

• Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
  RR 0.09 [0.02, 0.47]
  3 studies · 144 participants
  Low

Mycophenolate mofetil vs cyclosporin

Mycophenolate mofetil showed no clear difference in adverse effects: reduced GFR compared with cyclosporin (low certainty).

• Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
  RR 0.33 [0.01, 7.45]
  1 study · 24 participants
  Low

Mycophenolate mofetil vs levamisole

Mycophenolate mofetil showed no clear difference in relapses at 12 months compared with levamisole (low certainty).

• Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
  RR 0.9 [0.7, 1.16]
  1 study · 149 participants
  Low

Mycophenolate mofetil vs cyclophosphamide

Mycophenolate mofetil showed no clear difference in death at 6 months compared with cyclophosphamide (low certainty).

• Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
  RR 1.25 [0.35, 4.46]
  1 study · 140 participants
  Low

Mycophenolate mofetil vs cyclophosphamide

The review found no eligible studies for this question.

• Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Mycophenolate mofetil vs cyclophosphamide

Mycophenolate mofetil showed no clear difference in dialysis compared with cyclophosphamide (low certainty).

• Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
  RR 1 [0.14, 6.9]
  1 study · 140 participants
  Low

Mycophenolate mofetil vs cyclophosphamide

Mycophenolate mofetil showed no clear difference in relapse at any time point compared with cyclophosphamide (low certainty).

• Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
  RR 1.8 [1, 3.22]
  1 study · 127 participants
  Low

Mycophenolate mofetil vs cyclophosphamide

Mycophenolate mofetil probably leads to higher remission at 6 months compared with cyclophosphamide (moderate certainty).

• Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
  RR 1.17 [1.01, 1.35]
  3 studies · 216 participants
  Moderate

Mycophenolate mofetil vs cyclophosphamide

Mycophenolate mofetil may leads to higher serious adverse events compared with cyclophosphamide (low certainty).

• Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
  RR 1.25
  1 study · 140 participants
  Low

Mycophenolate mofetil vs cyclophosphamide

Mycophenolate mofetil showed no clear difference in infection compared with cyclophosphamide (moderate certainty).

• Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
  RR 1.27 [0.75, 2.16]
  3 studies · 216 participants
  Moderate

Mycophenolate mofetil vs placebo

Mycophenolate mofetil showed no clear difference in improvement in GNDS after 12 months1 compared with placebo (moderate certainty).

• Immunosuppressant and immunomodulatory treatments for multifocal motor neuropathy 2015 · Cochrane Headline outcomes only
  RR 0.54 [0.06, 5.26]
  1 study · 28 participants
  Moderate

Mycophenolate mofetil vs placebo

• Immunosuppressant and immunomodulatory treatments for multifocal motor neuropathy 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 28 participants
  Moderate

Mycophenolate mofetil vs IV cyclophosphamide

It is very uncertain whether mycophenolate mofetil (MMF) changes death compared with IV cyclophosphamide (CPA) (very low certainty).

• Immunosuppressive treatment for proliferative lupus nephritis 2018 · Cochrane Headline outcomes only
  RR 1.12 [0.61, 2.06]
  8 studies · 826 participants
  Very low

Mycophenolate mofetil vs IV cyclophosphamide

It is very uncertain whether mycophenolate mofetil (MMF) changes ESKD compared with IV cyclophosphamide (CPA) (very low certainty).

• Immunosuppressive treatment for proliferative lupus nephritis 2018 · Cochrane Headline outcomes only
  RR 0.71 [0.27, 1.84]
  3 studies · 231 participants
  Very low

Mycophenolate mofetil vs IV cyclophosphamide

Mycophenolate mofetil (MMF) showed no clear difference in complete renal remission compared with IV cyclophosphamide (CPA) (low certainty).

• Immunosuppressive treatment for proliferative lupus nephritis 2018 · Cochrane Headline outcomes only
  RR 1.17 [0.97, 1.42]
  8 studies · 828 participants
  Low

Mycophenolate mofetil vs IV cyclophosphamide

Mycophenolate mofetil (MMF) showed no clear difference in partial renal remission compared with IV cyclophosphamide (CPA) (low certainty).

• Immunosuppressive treatment for proliferative lupus nephritis 2018 · Cochrane Headline outcomes only
  RR 1.02 [0.89, 1.18]
  9 studies · 868 participants
  Low

Mycophenolate mofetil vs IV cyclophosphamide

It is very uncertain whether mycophenolate mofetil (MMF) changes ovarian failure compared with IV cyclophosphamide (CPA) (very low certainty).

• Immunosuppressive treatment for proliferative lupus nephritis 2018 · Cochrane Headline outcomes only
  RR 0.36 [0.06, 2.18]
  3 studies · 539 participants
  Very low

Mycophenolate mofetil vs IV cyclophosphamide

Mycophenolate mofetil (MMF) showed no clear difference in major infection compared with IV cyclophosphamide (CPA) (low certainty).

• Immunosuppressive treatment for proliferative lupus nephritis 2018 · Cochrane Headline outcomes only
  RR 1.02 [0.67, 1.54]
  6 studies · 699 participants
  Low

Mycophenolate mofetil vs IV cyclophosphamide

Mycophenolate mofetil (MMF) probably leads to lower alopecia compared with IV cyclophosphamide (CPA) (moderate certainty).

• Immunosuppressive treatment for proliferative lupus nephritis 2018 · Cochrane Headline outcomes only
  RR 0.29 [0.19, 0.46]
  3 studies · 622 participants
  Moderate

Mycophenolate mofetil vs IV cyclophosphamide

Mycophenolate mofetil (MMF) probably leads to higher diarrhoea compared with IV cyclophosphamide (CPA) (moderate certainty).

• Immunosuppressive treatment for proliferative lupus nephritis 2018 · Cochrane Headline outcomes only
  RR 2.42 [1.64, 3.58]
  4 studies · 609 participants
  Moderate